The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review

CONCLUSIONS: Perioperative immunotherapy is becoming the dominant treatment paradigm for resectable NSCLC, while increasing use of targeted drugs for actionable alterations necessitates upfront molecular profiling of early tumors for patient …